摘要 |
<p>The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-alpha synthesis; iii) an inhibitor of membrane-bound TNF-alpha; iv) an inhibitor of a natural receptor of TNF-alpha; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-1, IFG-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase.</p> |
申请人 |
DEPUY SPINE, INC.;DIMAURO, THOMAS, M.;ATTAWIA, MOHAMED;SERHAN, HASSAN;REYNOLDS, MARTIN, A.;GRACE, MELISSA;KADIYALA, SUDHAKAR;URBAHNS, DAVID;BRUDER, SCOTT;COLLINS, GREGORY;BROWN, LAURA, J.;GEESIN, JEFF;PLOUHAR, PAMELA, L.;SMITH, CATHERINE;SIEKIERKA, JOHN |
发明人 |
DIMAURO, THOMAS, M.;ATTAWIA, MOHAMED;SERHAN, HASSAN;REYNOLDS, MARTIN, A.;GRACE, MELISSA;KADIYALA, SUDHAKAR;URBAHNS, DAVID;BRUDER, SCOTT;COLLINS, GREGORY;BROWN, LAURA, J.;GEESIN, JEFF;PLOUHAR, PAMELA, L.;SMITH, CATHERINE;SIEKIERKA, JOHN |